Get the Stockscreener App
7.80
2.86%
-0.23
After Hours:
7.80
Rxsight Inc stock is traded at $7.80, with a volume of 768.47K.
It is down -2.86% in the last 24 hours and down -22.70% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$8.03
Open:
$8.19
24h Volume:
768.47K
Relative Volume:
0.81
Market Cap:
$320.71M
Revenue:
$142.09M
Net Income/Loss:
$-35.73M
P/E Ratio:
-8.8818
EPS:
-0.8782
Net Cash Flow:
$-22.20M
1W Performance:
-0.26%
1M Performance:
-22.70%
6M Performance:
+6.12%
1Y Performance:
-75.55%
1-Day Range:
$7.65
$8.285
1-Week Range:
$7.65
$8.54
52-Week Range:
$6.32
$32.24
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.80 | 330.17M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
RxSight, Inc. to Report Q4 and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - GlobeNewswire
RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration - Insider Monkey
New York State Common Retirement Fund Sells 341,274 Shares of RxSight, Inc. $RXST - MarketBeat
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Investors to Reach Out - accessnewswire.com
The Technical Signals Behind (RXST) That Institutions Follow - Stock Traders Daily
RxSight announces executive leadership reorganization and new appointments - MSN
Performance Recap: Is RxSight Inc in a long term uptrendJuly 2025 Institutional & Long-Term Safe Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect - ACCESS Newswire
Brown Capital Management LLC Trims Stock Position in RxSight, Inc. $RXST - MarketBeat
Aug Action: Is RxSight Inc a potential multi baggerShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Big Picture: Will RxSight Inc outperform tech stocksTrade Analysis Report & Low Volatility Stock Recommendations - baoquankhu1.vn
RxSight stock initiated with Market Perform rating by William Blair - Investing.com UK
Needham Lowers Price Target on RxSight to $13 From $14, Keeps Buy Rating - marketscreener.com
William Blair Initiates Coverage on RxSight With Market Perform - marketscreener.com
William Blair Starts RxSight Inc. (RXST) at Market Perform - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Can RxSight Inc. deliver consistent EPS growth2025 Top Gainers & Weekly High Return Forecasts - mfd.ru
RxSight down on CFO transition - MSN
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
RxSight price target raised to $9 from $8 at JPMorgan - MSN
Precision Trading with Rxsight Inc. (RXST) Risk Zones - Stock Traders Daily
RxSight (NASDAQ:RXST) Trading Down 0.9%Time to Sell? - MarketBeat
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - PR Newswire
Decliners Report: Is RxSight Inc a potential multi bagger2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
How Recent Developments Are Shaping The RxSight (RXST) Investment Story - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Expert Outlook: RxSight Through The Eyes Of 5 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight (RXST) soars 14.1%: Is further upside left in the stock? - MSN
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight stock price target raised to $11.50 from $11.00 at Jefferies By Investing.com - Investing.com South Africa
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com
RxSight Up 11% on Preliminary Q4, Full Year Results - Orange County Business Journal
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference By Investing.com - Investing.com South Africa
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference - Investing.com Nigeria
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):